Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolus, Inc.EOLS · Entity 5341 | See Remarks | May 17, 2022 | May 19, 2022 |
| HARROW, INC.HROW · Entity 4740 | Director | June 18, 2026 | June 22, 2026 |
| Revance Therapeutics, Inc.RVNC · Entity 83521 | CFO & CBO | May 22, 2018 | May 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolus, Inc.
Report date May 17, 2022 · Filed May 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,571 |
Ending reported balance
After 2022-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-17 · Sale · Disposed 16,189 · Balance 193,586 F1: The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2022-05-18 · Sale · Disposed 52,015 · Balance 141,571 F2: The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
HARROW, INC.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,248 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 5,248 · Balance 5,248 F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered.
F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service.
Revance Therapeutics, Inc.
Report date May 22, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,497 |
Reported balance
After 2018-05-22 transaction · row 1
1 source rowRow 1 · 2018-05-22 · Sale · Disposed 2,874 · Balance 65,497 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail.
F2: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DYNAVAX TECHNOLOGIES CORP
Report date February 10, 2026 · Filed February 10, 2026
Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Disposition to issuer · Disposed 10,075 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-10 · Disposition to issuer · Disposed 42,750 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-10 · Disposition to issuer · Disposed 7,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.
F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.20 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 2,033 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock").
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2017 Filed Jan 3, 2018 20:27 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 443 | $22.99 | $10,185.68 |
DisclosureSEC source: 0001479290-18-000004 · wf-form4_151502922875617.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,955 F1 · kind: These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 29, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mrs. Silvernail purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2017. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 20:51 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to buy) · Derivative | 17,506 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001479290-17-000044 · wf-form4_151451226701828.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 17,506 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 20:51 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 17,506 | $8.70 | $152,302.20 |
DisclosureSEC source: 0001479290-17-000044 · wf-form4_151451226701828.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Mrs. Silvernail has exercised the option on December 26, 2017 and paid the exercise price in cash. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 19:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001209191-17-060103 · doc4.xml · derivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,373 Underlying: Common Stock · 10,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 19:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 10,000 | $26.83 | $268,267.00 |
DisclosureSEC source: 0001209191-17-060103 · doc4.xml · nonDerivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,006 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2 · price: The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $27.25. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 19:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 10,000 | $8.70 | $87,000.00 |
DisclosureSEC source: 0001209191-17-060103 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:20 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 11,164 | $26.67 | $297,759.51 |
DisclosureSEC source: 0001209191-17-057047 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,006 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2 · price: The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $26.85. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 21:32 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 604 | $18.32 | $11,063.77 |
DisclosureSEC source: 0001209191-17-043852 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,170 F1 · kind: These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 26, 2017 Filed May 31, 2017 21:01 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001209191-17-036620 · doc4.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,373 Underlying: Common Stock · 23,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| May 26, 2017 Filed May 31, 2017 21:01 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 23,000 | $8.70 | $200,100.00 |
DisclosureSEC source: 0001209191-17-036620 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed May 24, 2017 21:14 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,793 | $20.20 | $36,212.15 |
DisclosureSEC source: 0001209191-17-035187 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,566 F1 · kind: The sales reported in this Form 4 were effected pursuant to an irrevocable sell to cover election previously adopted by Mrs. Silvernail. F2 · shares: The shares were disposed to satisfy tax withholding obligations that arose in connection with the vesting of 4,667 shares of restricted stock on May 19, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.20. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 19:24 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,269 | $19.20 | $24,365.82 |
DisclosureSEC source: 0001209191-17-021566 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,359 F1 · shares: Represents 1,269 shares withheld by and surrendered to the Issuer on March 16, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of 3,333 shares subject to the restricted stock award. Read SEC document |
| January 28, 2017 Filed Jan 30, 2017 21:27 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 1,063 | $20.00 | $21,260.00 |
DisclosureSEC source: 0001209191-17-006266 · doc4.xml · nonDerivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,628 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on January 28, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of a 2015 Restricted Stock Award ("RSA") for 7,290 shares. The RSA vests in three (3) equal annual installments from January 28, 2015, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:27 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $19.70 | $0.00 |
DisclosureSEC source: 0001209191-17-006266 · doc4.xml · derivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-25 F3 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 26, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:27 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006266 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,691 F1 · shares: The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from February 15, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.